Next Phase Newsletter

A venture capital firm that operates through several offices in USA and Asia manages over $750 million in committed capital across 8 funds. The most recent fund closed at $175M, and the firm focuses on early stage companies in Technology and Healthcare sectors with an initial investment size ranging from $500k to $5M. The firm primarily looks to invest in companies based in USA and China.

The firm is currently looking for new investment opportunities in Diagnostics, Medical Devices, Digital Health and Advanced Materials sectors. The firm is very opportunistic in terms of subsectors and indications, and is open to all classes of devices. The firm prefers to invest companies in pre-clinical and clinical stage, but it is open to consider companies with products on the market. Historically, the firm was active in companies developing diagnostic services and instrumentation, fetal monitoring and ultrasound systems, a stem cell bank, numerous health IT and vascular closure devices.

The firm invests in both private and public companies with a strong management team. The firm doesn’t have specific requirements for companies’ revenue or EBITDA. The firm looks to take a Board seat post investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A corporate venture/life science investment arm of an Asia-based life science, and medical equipment manufacturer invests from an evergreen fund and prefers to invest at company formation/seed stage, but no later than Series A. Typical investments range from $1-5M, but the fund will make larger tranched investments in case of therapeutic opportunities. The firm invests in companies worldwide. The firm can act as either a lead or a co-investor role. The firm prefers to invest at company formation or seed stages, with the latest stage they will invest being Series A.

The firm has four current focus areas: women’s health/fertility, life sciences tools & diagnostics, biotech (novel therapeutics), and PMA medical devices. The firm is interested broadly across all indications within these areas.

The firm prefers to invest in teams with a strong track record but has also worked with first-time entrepreneurs. The firm may or may not take a board seat in a portfolio company. If a company is seeking to expand into Asia, the firm can leverage the capabilities of the corporate to help companies with regulatory affairs, market access, and distribution, especially in the life sciences tools and fertility markets.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm founded in the 1990s with about 2 billion RMB in assets under management is currently investing out of their $30 million USD fund. Besides the $30M US dollar fund, the firm already has about $20M anchor secured and aim to raise around $70M for the 2nd dollar fund. The firm also shifted their paradigm that in the next 5 years, they will have 60% of the fund and portfolio companies from the USA. The firm focuses on Series A-B deals within the USA, Canada, and China and typically invests $2-5M per deal. The firm typically co-invests, but is willing to lead in specific situations.

The firm is opportunistic within the therapeutics and medical technology domains. However, for therapeutics, the firm focuses mostly on assets that are currently in Phase I or Phase II clinical trials. For Medical Devices, they prefer technologies that already have 510k or PMA clearance. Most importantly though, when investing, the firm requires that the technology has strong clinical evidence of efficacy. Strong evidence of efficacy is the most important criteria for the firm when investing in therapeutics and medical technology.

The firm is looking for a management team with a strong history of success as serial entrepreneurs or with strong clinical backgrounds. For investment opportunities without FDA clearance, the firm prefers seeing management teams with prior success in achieving FDA approval or candidates who have strong background from big pharma.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A newly established family office based in the USA seeks to leverage its technology expertise (i.e. AI, machine learning, cloud computing, cybersecurity, etc.) and invest in innovative early-stage healthcare companies that integrate technology, has the potential to become highly disruptive, and improve quality of life. To date, the firm has invested in 3 healthcare companies and continues to grow their portfolio. Currently, the firm is focused on pre-seed to seed funding with initial check size ranging from $100-250K, and up to $1M over the lifetime of the investment. The firm has a large footprint in North America and Israel, and will consider investment opportunities globally.

The firm is most interested in companies that are developing novel solutions to healthcare through the use of technology. The firm will consider medical technology companies, given that there is a strong data or technology component. Areas of high interest include the use of AI in drug discovery, drug delivery applications, SaaS/enterprise solutions in healthcare services, etc. At this time, the firm is not interested in biotech therapeutics or B2C applications.

The firm does not have specific company or management team requirements, but having an experienced management team with a track record of success is a huge plus. The firm typically co-invests alongside larger VC firms, but is open to leading rounds as well depending on the stage of the company and the firm’s capacity to contribute as a value-add. The firm does not always seek board representation.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A holding company headquartered in USA and China with additional offices in throughout China aims to serve human healthcare and technological development through high-tech investment and real estate investment. Through its investment arm, the firm makes venture investments in healthcare. Typical allocations range from $1-10M in companies from Seed to Series B stages. The firm is open to leading or following in a round. The firm is looking for opportunities from US and Canada that have a China angle.

Additionally, while investing, the firm seeks to leverage their real estate resources in China while investing in companies. This could be through the establishment of a manufacturing plant in China or even starting a joint venture office in China.

Within healthcare, the firm considers biopharmaceuticals, medical devices, diagnostics, and AR/VR/AI innovations in healthcare. The firm is focused on diseases with large market potential including oncology, infectious disease, diabetes, CNS, and cardiovascular diseases. The firm is opportunistic in terms of stage of development and typically participates in Seed to Series B rounds.

The firm is seeking innovative products and can aid with management, operations, and registration. Leveraging its resources in China, the firm can facilitate distribution in the China market. However, distribution rights are not a requirement for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA investment office of a biotech incubator sector fund headquartered in China currently manages two venture funds including an RMB fund I and a USD fund II. The firm can allocate from $200,000 to $800,000 of equity capital in seed round companies and can make investments ranging from $1 to $10 million in series A companies. The firm looks to tailor its incubator and CRO services to the needs of its partners, helping them to reach key value-added milestones. The firm will consider opportunities based in China and North America, companies within a strong China angle involvement is their sweet spot. The firm is actively seeking in-licensing opportunities and plans to make 10-12 investments next year but is flexible.

The firm focuses mostly on therapeutics, while the firm is also open to Diagnostics. The firm can utilize its CRO services to advance portfolio company’s products into or through clinical trials. The firm is currently most interested in small molecule first-in-class drugs. The firm is opportunistic in terms of subsector and indication and is willing to consider companies targeting orphan indications. For therapeutics, the firm is looking to invest in pre-clinical stage. For diagnostics, the firm will consider companies from in-development to clinical stages. The firm will not invest in Medical Devices Healthcare IT companies.

The firm looks to act as a lead investor in seed round investments and can participate as either lead or co-investor in series A investments. The firm is looking for companies with skilled and experienced management teams. The firm prefers to support companies that own exclusive IP protection with renowned universities or research institutions. The firm also prefers to work with companies that have a technical expert and experienced in clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A private equity firm founded in 2003 with headquarters in the USA has previously invested in real estate, retail, and consumer products industries. However, the firm has recently focused on life science investment opportunities. The firm’s current fund is over $300M and the firm is planning to raise a $200M fund focused on life sciences and consumer products. The firm’s minimum investment begins at $5M, and the investment size depends on the stage of the targeted company. The firm primarily invests in later stage life science companies. The firm is looking for companies in North America and Canada and would seek distribution rights in China. The firm is actively looking for investment opportunities and plans to make 4-5 new investments as soon as possible. The firm would only seek to be the lead investor and will request a board seat.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, Diagnostics, and Healthcare IT companies. The firm is open to all kinds of therapeutic assets but prefers companies that are into phase I of clinical trials or later. The firm is especially interested in vaccines including flu vaccines, Hepatitis A vaccine, Hepatitis B vaccine, and any other drugs for common diseases in China. The firm has a strong preference for later stage companies with products and pipelines that can directly produce and sell in China. The firm is open to medical devices with all FDA regulatory pathways, including 510k, PMA, and software-enabled devices. The firm is open to any phases in medical devices and therapeutics with a preference for those within human data. The most important consideration is the potential market in China.

The firm considers the management team’s character and entrepreneurial spirit. Team members who speak Mandarin may be a plus but is not required.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.